Literature DB >> 33518163

Fish Oil for Inflammatory Bowel Disease: Panacea or Placebo?

Gerard E Mullin1, Berkeley N Limketkai2, Alyssa M Parian3.   

Abstract

Dietary supplements have increasingly gained popularity over the years not only to replete micronutrient deficiencies but for their use in treatment of disease. The popularity of dietary supplements for inflammatory bowel diseases (IBD) arises from their perceived ease of use, potential disease-modifying benefits, and perceived safety. Overall, randomized controlled trials have not consistently shown a benefit of fish oil for the maintenance of remission with Crohn's disease. The inconsistency of these findings highlights the need for more studies that are powered to clarify the context in which omega-3 fatty acids might have a role in the treatment algorithm of IBD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dietary supplements; Docosahexaenoic acid (DHA); Fish oil; Inflammatory bowel disease, eicosapentaenoic acid (EPA); Omega-3 fatty acids; α-Linolenic acid (ALA)

Year:  2021        PMID: 33518163     DOI: 10.1016/j.gtc.2020.10.010

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  1 in total

1.  Synbiotic Compositions of Bacillus megaterium and Polyunsaturated Fatty Acid Salt Enable Self-Sufficient Production of Specialized Pro-Resolving Mediators.

Authors:  Bodo Speckmann; Jessica Kleinbölting; Friedemann Börner; Paul M Jordan; Oliver Werz; Stefan Pelzer; Heike Tom Dieck; Tanja Wagner; Christiane Schön
Journal:  Nutrients       Date:  2022-05-28       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.